Adequan Canine for Dogs: The Science of Polysulfated Glycosaminoglycan
How Adequan Canine (polysulfated glycosaminoglycan) works at the cellular level to protect joints, what the science says, and what it means for your dog's mobility.
If your dog has been diagnosed with osteoarthritis or hip dysplasia, your veterinarian may have mentioned Adequan Canine as part of a treatment plan. But what exactly is this medication, and how does it work inside your dog's body?
Direct Answer: Adequan Canine is an FDA-approved injectable medication containing polysulfated glycosaminoglycan (PSGAG). It is classified as a disease-modifying osteoarthritis drug (DMOAD). Rather than simply masking pain like NSAIDs, Adequan works at the molecular level to inhibit cartilage-degrading enzymes, stimulate the production of new joint matrix components, and reduce inflammation within the synovial fluid. It is administered as a series of intramuscular injections, typically twice weekly for four weeks, and is indicated for the control of signs associated with degenerative joint disease in dogs.
The Biochemistry of Adequan Canine: How Polysulfated Glycosaminoglycan Works
To understand why Adequan Canine exists and how it functions, you need to understand the structure of a healthy canine joint — and what goes wrong when osteoarthritis takes hold.
A dog's synovial joint is lined with articular cartilage, a specialized connective tissue composed of chondrocytes (cartilage cells) embedded in an extracellular matrix. That matrix is built from two primary structural components:
- Collagen fibers (primarily Type II): These provide tensile strength — think of them as the rebar in concrete.
- Proteoglycans (especially aggrecan): These large molecules are studded with glycosaminoglycan (GAG) side chains — chondroitin sulfate and keratan sulfate — that attract and hold water, giving cartilage its compressive resilience.
In a healthy joint, chondrocytes maintain a balance between matrix synthesis and matrix degradation. In osteoarthritis, that balance collapses. Pro-inflammatory cytokines — particularly interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α) — trigger the release of matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS-4 and ADAMTS-5). These enzymes systematically dismantle the cartilage matrix faster than chondrocytes can rebuild it.
This is where PSGAG intervenes.
PSGAG's Multi-Target Mechanism of Action
Adequan's active ingredient, polysulfated glycosaminoglycan, is a semi-synthetic compound derived from bovine tracheal cartilage. Its molecular structure resembles the natural GAGs found in canine cartilage, which allows it to integrate into joint biochemistry at multiple points:
- Enzyme inhibition: PSGAG directly inhibits serine proteases, cathepsin G, elastase, and several MMPs that degrade cartilage. Research published in the Journal of Veterinary Pharmacology and Therapeutics demonstrated that PSGAG reduces the activity of these catabolic enzymes at concentrations achievable through standard intramuscular dosing.
- Matrix synthesis stimulation: PSGAG upregulates chondrocyte production of new proteoglycans and collagen. In vitro studies on canine cartilage explants show increased synthesis of aggrecan when exposed to PSGAG concentrations of 10–100 μg/mL.
- Synovial fluid improvement: PSGAG stimulates hyaluronic acid synthesis by synoviocytes (cells lining the joint capsule), improving synovial fluid viscosity and lubrication.
- Anti-inflammatory effects: PSGAG inhibits prostaglandin E2 (PGE2) production and reduces complement system activation, both of which contribute to joint inflammation and pain signaling.
This multi-target approach is what classifies Adequan as a DMOAD rather than a simple analgesic. It doesn't just address symptoms — it modifies the disease process itself.
The Evolutionary Context: Why Dogs Are Vulnerable to Joint Degeneration
Domestic dogs (Canis lupus familiaris) diverged from gray wolves roughly 15,000–40,000 years ago. Their ancestral bodies were built for endurance running, sudden acceleration, and the biomechanical stresses of hunting large prey across varied terrain. The wolf's musculoskeletal system evolved under consistent selective pressure: individuals with joint weaknesses died before reproducing.
Domestication fundamentally changed those selective pressures. Two forces now drive the high prevalence of canine osteoarthritis:
- Artificial selection for extreme conformations: Breeds like the German Shepherd Dog (steep croup angles), Bulldog (skeletal dysplasia), and Dachshund (chondrodysplastic limb proportions) carry joint-loading patterns that would never survive in a wild canid population. The American Kennel Club breed standards for some of these dogs inadvertently perpetuate conformational traits that predispose to hip dysplasia, elbow dysplasia, and cranial cruciate ligament disease.
- Increased lifespan: Wild canids rarely live past 8–10 years. Modern pet dogs routinely reach 12–15 years or more, exposing joints to decades of cumulative microtrauma that evolution never selected against.
Osteoarthritis is estimated to affect approximately 20% of dogs over one year of age and over 60% of dogs over seven years, according to data referenced by the American Veterinary Medical Association. This is, in many ways, a disease of domestication — a mismatch between ancestral biomechanics and modern longevity and breed conformation.
Dosing, Administration, and What to Expect
Adequan Canine is supplied as a sterile solution of 100 mg/mL polysulfated glycosaminoglycan in 5 mL multi-dose vials. The labeled dosage is 2 mg per pound of body weight (4.4 mg/kg), administered by intramuscular injection.
| Dog Weight (lb / kg) | Dose Volume (mL) | Frequency | Total Injections |
|---|---|---|---|
| 10 lb / 4.5 kg | 0.2 mL | Twice weekly | 8 (over 4 weeks) |
| 25 lb / 11.3 kg | 0.5 mL | Twice weekly | 8 (over 4 weeks) |
| 50 lb / 22.7 kg | 1.0 mL | Twice weekly | 8 (over 4 weeks) |
| 75 lb / 34 kg | 1.5 mL | Twice weekly | 8 (over 4 weeks) |
| 100 lb / 45.4 kg | 2.0 mL | Twice weekly | 8 (over 4 weeks) |
Important: Your veterinarian will determine the exact dose for your dog based on body weight, condition severity, and overall health status. Never adjust dosage without veterinary guidance.
Pharmacokinetics: Where Does the PSGAG Go?
After intramuscular injection, PSGAG is rapidly absorbed into the bloodstream. Pharmacokinetic studies in dogs show peak plasma concentrations within approximately 2 hours. The compound is preferentially taken up by articular cartilage and synovial fluid, where it reaches therapeutic concentrations within 24–48 hours. It is primarily eliminated through the kidneys, with a plasma half-life of roughly 4–6 hours, though its biological effects within the joint persist significantly longer due to matrix binding.
Clinical improvement is often observable after 2–4 injections, though the full therapeutic benefit typically emerges after completing the initial 8-injection series. Some veterinarians recommend periodic maintenance injections (e.g., one injection every 2–4 weeks) following the initial loading series, though this is an extra-label use that your vet will evaluate on a case-by-case basis.
Breed Variations and Risk Profiles
While osteoarthritis can affect any dog, certain breeds carry significantly higher risk due to inherited conformational traits and genetic predispositions. Adequan Canine is frequently incorporated into management plans for these breeds:
| Breed | Common Joint Conditions | Typical Onset | Prevalence Data |
|---|---|---|---|
| German Shepherd Dog | Hip dysplasia, elbow dysplasia, degenerative myelopathy | 6–18 months (dysplasia) | ~19% hip dysplasia (OFA data) |
| Labrador Retriever | Hip/elbow dysplasia, cranial cruciate ligament rupture | 6–24 months | ~12% hip dysplasia (OFA data) |
| Golden Retriever | Hip dysplasia, elbow dysplasia | 6–18 months | ~20% hip dysplasia (OFA data) |
| Rottweiler | Hip dysplasia, elbow dysplasia, osteosarcoma (differential) | 6–18 months | ~20% hip dysplasia (OFA data) |
| Dachshund | IVDD (not joint-specific, but mobility-impacting) | 2–5 years | ~25% lifetime IVDD risk |
| Bernese Mountain Dog | Hip/elbow dysplasia | 6–18 months | ~25% elbow dysplasia (OFA data) |
For large and giant breed owners, proactive joint health discussions with your veterinarian — including the potential role of Adequan as a preventive or early-intervention tool — should begin well before clinical signs appear. The Orthopedic Foundation for Animals (OFA) maintains breed-specific screening databases that responsible breeders use to reduce hereditary joint disease incidence.
Myth vs. Fact: Common Misconceptions About Adequan
| Myth | Fact |
|---|---|
| "Adequan is just an expensive painkiller." | Adequan is not an analgesic. It does not directly block pain signals. It modifies the disease process by inhibiting cartilage-degrading enzymes and stimulating matrix repair. Pain reduction is a secondary effect of improved joint health. |
| "Oral glucosamine supplements work the same way." | Oral glucosamine has poor and inconsistent bioavailability in dogs. Multiple studies, including a 2010 review in the Journal of the American Veterinary Medical Association, found limited evidence that oral glucosamine reaches therapeutic concentrations in synovial fluid. Injectable PSGAG bypasses GI absorption limitations entirely. |
| "Adequan can cure arthritis." | Osteoarthritis is a progressive, irreversible condition. Adequan slows progression and improves joint function, but it does not regenerate destroyed cartilage or reverse bone remodeling. It is a management tool, not a cure. |
| "It's only for old dogs." | Adequan is indicated for dogs of any age with degenerative joint disease. Young dogs with hip or elbow dysplasia may benefit from early intervention to slow progression. Your veterinarian determines appropriateness based on diagnosis, not age. |
| "Adequan replaces the need for weight management and exercise modification." | No medication compensates for excessive joint loading. A dog carrying 15% excess body weight experiences dramatically increased joint forces. Adequan works best as part of a multimodal plan including weight optimization, controlled exercise, and possibly NSAIDs or other adjuncts. |
Safety Profile, Contraindications, and Side Effects
Adequan Canine carries a well-characterized safety profile based on decades of clinical use since its FDA approval. However, like all medications, it is not without risks.
Known Side Effects
The most commonly reported adverse effects are mild and transient:
- Injection site reactions: Mild pain, swelling, or transient lameness at the injection site (reported in <2% of cases in clinical trials).
- Transient vomiting or diarrhea: Uncommon, usually self-limiting within 24 hours.
- Mild coagulation changes: PSGAG has mild anticoagulant properties (it is structurally related to heparin). At labeled doses, this is rarely clinically significant, but it is a consideration for dogs with pre-existing coagulopathies or those undergoing surgery.
Contraindications and Cautions
- Do not use in dogs with known hypersensitivity to polysulfated glycosaminoglycan.
- Use with caution in dogs with bleeding disorders (e.g., von Willebrand disease, hemophilia) or dogs receiving anticoagulant medications.
- Not approved for use in cats — Adequan Canine is specifically formulated and labeled for dogs only.
- Safety in breeding, pregnant, or lactating dogs has not been established. Discuss alternatives with your veterinarian if your dog falls into these categories.
Contact your veterinarian promptly if your dog experiences:
- Persistent vomiting or diarrhea lasting more than 24 hours after injection
- Significant swelling or heat at the injection site
- Unusual bruising or bleeding (gums, stool, urine)
- Acute worsening of lameness
- Any signs of allergic reaction (facial swelling, hives, difficulty breathing)
Practical Implications: What Adequan Means for Your Dog's Daily Life
Integrating Adequan Into a Multimodal Joint Management Plan
Adequan Canine is most effective when combined with other evidence-based interventions. Here is a framework your veterinarian may use:
- Weight management: Maintain your dog at an ideal body condition score (BCS 4–5 on a 9-point scale). Every pound of excess weight exerts approximately 4 pounds of additional force on weight-bearing joints during movement. For a 50 lb dog carrying 5 extra pounds, that is 20 lb of excess joint loading per step.
- Controlled exercise: Low-impact, consistent activity (swimming, leash walking on soft surfaces, underwater treadmill therapy) maintains muscle mass that stabilizes joints. Avoid high-impact activities (repetitive jumping, hard-surface running) that accelerate cartilage wear.
- Environmental modification: Provide orthopedic bedding, use ramps for vehicle entry and furniture access, and install non-slip flooring (area rugs, yoga mats) on hard floors to reduce joint strain from slipping.
- Adjunctive medications: Your veterinarian may combine Adequan with NSAIDs (carprofen, meloxicam, grapiprant), gabapentin for neuropathic pain components, or newer therapies like anti-NGF monoclonal antibodies (librela/bedinvetmab) for refractory cases.
- Omega-3 fatty acid supplementation: EPA and DHA at doses of 75–100 mg/kg combined EPA+DHA daily have demonstrated anti-inflammatory effects in canine osteoarthritis. Prescription joint diets (e.g., Hill's j/d, Royal Canin Mobility Support, Purina JM) provide therapeutic omega-3 levels.
Cost Expectations
As of 2026, expect the following approximate costs:
- Adequan vial (5 mL, 100 mg/mL): $65–$95 per vial through your veterinarian
- Initial 8-injection series (including veterinary administration): $250–$500 depending on dog size and clinic pricing
- Maintenance injections (if recommended): $40–$80 per injection visit
Some pet insurance policies cover Adequan when prescribed for a diagnosed condition, though pre-existing condition exclusions may apply. Check your policy's prescription medication coverage details.
How Adequan Compares to Other Joint Therapies
Understanding where Adequan fits in the broader landscape of canine joint care helps you have more informed conversations with your veterinarian.
| Therapy | Mechanism | Onset of Action | DMOAD? | Typical Cost Range |
|---|---|---|---|---|
| Adequan Canine (PSGAG) | Enzyme inhibition, matrix synthesis stimulation | 2–4 weeks | Yes | $250–$500 (initial series) |
| Carprofen (Rimadyl) | COX-2 inhibition (NSAID) | 1–2 hours | No | $30–$80/month |
| Grapiprant (Galliprant) | EP4 receptor antagonist | 1–2 hours | No | $60–$150/month |
| Bedinvetmab (Librela) | Anti-NGF monoclonal antibody | 7–14 days | No (analgesic) | $75–$200/injection (monthly) |
| Oral glucosamine/chondroitin | Purported matrix substrate supply | 4–8 weeks (if effective) | Unproven | $20–$50/month |
| Omega-3 fatty acids (EPA/DHA) | Anti-inflammatory (eicosanoid modulation) | 4–8 weeks | No (adjunctive) | $20–$60/month |
A key distinction: Adequan is the only therapy in this list classified as a true DMOAD with FDA approval for dogs. NSAIDs, grapiprant, and anti-NGF antibodies are analgesics — they manage pain but do not alter the underlying disease progression. This is why many veterinary orthopedic specialists recommend combining Adequan (to slow disease) with an analgesic (to manage pain) for comprehensive care.
When Joint Problems Signal Something More Serious
Not all lameness or mobility decline is osteoarthritis. Certain presentations require immediate or urgent veterinary evaluation to rule out conditions that Adequan cannot treat:
- Acute, non-weight-bearing lameness: May indicate cranial cruciate ligament rupture, fracture, or bone tumor (osteosarcoma). These require imaging and potentially surgical intervention.
- Progressive hind limb weakness with knuckling: Especially in German Shepherds, Boxers, and Pembroke Welsh Corgis, this may signal degenerative myelopathy — a neurodegenerative disease, not a joint disease. Adequan has no effect on neurological conditions.
- Fever with joint swelling: Immune-mediated polyarthritis, tick-borne disease (Lyme, Anaplasma, Ehrlichia), or septic arthritis require specific diagnostic workups and entirely different treatment protocols.
- Lameness in puppies under 12 months: Panosteitis, hypertrophic osteodystrophy (HOD), and osteochondritis dissecans (OCD) are developmental conditions that need breed-specific and age-specific evaluation.
Always consult your veterinarian for a definitive diagnosis before starting any joint medication. Adequan is appropriate for confirmed or strongly suspected degenerative joint disease — it is not a blanket treatment for all mobility issues.
Key References
Frequently Asked Questions
Can dogs take Adequan and NSAIDs at the same time?
Yes, in most cases. Adequan and NSAIDs (carprofen, meloxicam, etc.) work through entirely different mechanisms and are commonly prescribed together as part of a multimodal pain and disease management plan. Your veterinarian will evaluate your dog's kidney function, liver values, and overall health to confirm this combination is safe for your individual dog.
How long does it take for Adequan to work in dogs?
Some dogs show improved mobility within 7–10 days of starting the injection series. Most demonstrate noticeable improvement after 3–4 injections (approximately 2 weeks). The full therapeutic effect typically develops after completing all 8 injections over 4 weeks. If no improvement is seen after the full series, your veterinarian will reassess the diagnosis and explore other causes of mobility decline.
Is Adequan the same as Cartrophen Vet?
Cartrophen Vet (pentosan polysulfate sodium) is a similar DMOAD used primarily in the UK, Australia, and Europe. Both Adequan and Cartrophen are classified as disease-modifying agents, but they have different active ingredients and molecular structures. Adequan (PSGAG) is the FDA-approved DMOAD for dogs in the United States. Availability and regulatory approval vary by country.
Can I give my dog oral glucosamine instead of Adequan injections?
Oral glucosamine supplements are not equivalent to injectable PSGAG. Bioavailability of oral glucosamine in dogs is low and inconsistent, and multiple veterinary studies have failed to demonstrate reliable therapeutic concentrations in synovial fluid after oral dosing. If your dog is a candidate for DMOAD therapy, injectable Adequan provides far more predictable drug delivery. That said, oral supplements may serve as a low-risk adjunctive measure — discuss with your vet.
Is Adequan safe for long-term use?
Adequan has been used in veterinary medicine for over 30 years with a strong long-term safety record. Many dogs receive maintenance injections (every 2–4 weeks) for years without adverse effects. Your veterinarian will monitor your dog's health through regular checkups and may periodically assess kidney function, as PSGAG is renally eliminated. Long-term safety data supports its use when administered under veterinary supervision at recommended intervals.
What does it mean when my dog's lameness improves on Adequan but returns when injections stop?
This is expected and does not indicate treatment failure. Osteoarthritis is a chronic, progressive disease. Adequan slows the disease process and improves joint biochemistry while present in the system, but it does not permanently reverse damage. When therapeutic levels decline, the underlying disease process resumes. This is why many veterinarians recommend ongoing maintenance injections rather than a single course.
Disclaimer: This article is for educational purposes only and does not replace professional veterinary advice. Always consult your veterinarian before starting, stopping, or modifying any medication for your dog. Adequan Canine is a prescription medication that must be obtained through and administered under the guidance of a licensed veterinarian.
Marcus Aldridge
All our authors care for dogs every day — read more of their work on the authors page.
